Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + UFT + tamoxifen

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination chemotherapy regimen consisting of cyclophosphamide, doxorubicin (Adriamycin), UFT (uracil and tegafur), and tamoxifen. This regimen is designed as a chemoendocrine therapy with high antitumor effect and relatively mild adverse reactions for the treatment of advanced and recurrent breast cancer. In this therapy, one 3-week cycle consists of doxorubicin 30 mg/m² intravenously on day 1, cyclophosphamide 65 mg/m² orally on days 1-14, UFT 300 mg/m² orally on days 1-14, and tamoxifen 20 mg/day orally on days 1-21.

Targets

ER (Estrogen receptor)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)DNADPYD (Dihydropyrimidine dehydrogenase)

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + UFT + tamoxifen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + UFT + tamoxifen.

Explore the full profile